Fig. 7
From: Emerging phagocytosis checkpoints in cancer immunotherapy
Targeting QPCTL and targeting PD-L1. a QPCTL is the key enzyme for pyroglutamylation of CD47. Targeting QPCTL significantly reduces the binding ability of CD47 to SIRPα and prompts phagocytosis of tumor cells by macrophages thus regulating tumor immunity. b PD-1 is expressed on T cells, the antibody targeting PD-1 can bind to FcR on phagocytes and then be engulfed by the phagocytes, leading to the inhibition of cancer immunotherapy
